Key result
Lupus Impact Tracker moderately tracks clinical improvement, showing significantly greater responsiveness in treatment responders.
Why the study?
The responsiveness of the lupus impact tracker and LupusQoL to changes in systemic lupus erythematosus disease activity measured by the systemic lupus erythematosus responder index was not previously described.
Population
325 adult systemic lupus erythematosus patients in USA and Canada
Comparison
SRI responders vs non-responders
Design
Observational longitudinal multicentre study
Follow-up
3 months
Authors
Loading...
LIT shows moderate responsiveness to SRI changes in this cohort; hypothesis-generating for use in trials but should not yet change practice.
Observational (n=325)
Yes
Absolute Event Rate: -0.69% vs -0.2%
p-value: p=0.02
The lupus impact tracker (LIT) is moderately responsive to clinical changes as measured by the systemic lupus erythematosus responder index (SRI), supporting its use in clinical care and trials.
Devilliers et al. (2016) conducted an observational in Systemic lupus erythematosus (n=325). SRI responder status vs. SRI non-responder status was evaluated on LIT standardised response mean (p=0.02). The lupus impact tracker (LIT) was moderately responsive to clinical changes, with a standardised response mean of -0.69 in SRI responders versus -0.20 in non-responders (P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: